- Home
- GALT
as of 03-12-2026 2:25pm EST
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 176.7M | IPO Year: | 2008 |
| Target Price: | $8.50 | AVG Volume (30 days): | 281.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | -2.70 |
| 52 Week Low/High: | $1.15 - $7.13 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -7.53 | Index: | N/A |
| Free Cash Flow: | -41767000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
Director
Avg Cost/Share
$2.70
Shares
300
Total Value
$810.00
Owned After
65,682
SEC Form 4
President and CEO
Avg Cost/Share
$3.58
Shares
37,698
Total Value
$134,853.29
Owned After
832,592
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$3.67
Shares
20,354
Total Value
$74,695.11
Owned After
7,614
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$3.65
Shares
21,446
Total Value
$78,204.98
Owned After
0
SEC Form 4
President and CEO
Avg Cost/Share
$3.91
Shares
27,731
Total Value
$108,342.24
Owned After
832,592
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$3.90
Shares
25,732
Total Value
$100,298.19
Owned After
7,614
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$3.90
Shares
25,499
Total Value
$99,407.85
Owned After
0
SEC Form 4
President and CEO
Avg Cost/Share
$4.20
Shares
18,571
Total Value
$77,938.77
Owned After
832,592
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$4.20
Shares
13,914
Total Value
$58,394.28
Owned After
7,614
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$4.20
Shares
13,055
Total Value
$54,789.22
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ELDRED KARY | GALT | Director | Feb 6, 2026 | Buy | $2.70 | 300 | $810.00 | 65,682 | |
| LEWIS JOEL | GALT | President and CEO | Jan 6, 2026 | Sell | $3.58 | 37,698 | $134,853.29 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Jan 6, 2026 | Sell | $3.67 | 20,354 | $74,695.11 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Jan 6, 2026 | Sell | $3.65 | 21,446 | $78,204.98 | 0 | |
| LEWIS JOEL | GALT | President and CEO | Jan 5, 2026 | Sell | $3.91 | 27,731 | $108,342.24 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Jan 5, 2026 | Sell | $3.90 | 25,732 | $100,298.19 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Jan 5, 2026 | Sell | $3.90 | 25,499 | $99,407.85 | 0 | |
| LEWIS JOEL | GALT | President and CEO | Jan 2, 2026 | Sell | $4.20 | 18,571 | $77,938.77 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Jan 2, 2026 | Sell | $4.20 | 13,914 | $58,394.28 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Jan 2, 2026 | Sell | $4.20 | 13,055 | $54,789.22 | 0 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 14, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLNov 14, 2025 · 100% conf.
1D
-3.90%
$5.30
5D
-4.75%
$5.25
20D
-13.36%
$4.77
falseGALECTIN THERAPEUTICS INC0001133416GANASDAQ00011334162025-11-142025-11-14
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 14, 2025
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Nevada
001-31791
04-3562325
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
4960 PEACHTREE INDUSTRIAL BOULEVARD,
STE 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)
Registrant’s telephone number, including area code: (678) 620-3186
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock $0.001 par value per share
GALT
The Nasdaq Stock Market
SECTION 2 – FINANCIAL INFORMATION
Item 2.02
Results of Operations and Financial Condition.
On November 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the nine months ended September 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated November 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1.
Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics’ future financial performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the Press Release. For further information on other risk factors, please refer to the “Risk Factors” contained in Galectin Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission, and its subsequent filings with the SEC.
The information in this Item 2.02 is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release dated November 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Galectin Therapeutics Inc.
Date: November 14, 2025
By:
/s/ Jack W. Callicutt
Jack W. Callicutt
Chief Financial Officer
- 3 -
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
Q2 2025 Earnings
8-KAug 14, 2025
false000113341600011334162025-08-142025-08-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 14, 2025
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Nevada
001-31791
04-3562325
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)
Registrant’s telephone number, including area code: (678) 620-3186
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock $0.001par value per share
GALT
The Nasdaq Stock Market
SECTION 2 – FINANCIAL INFORMATION
Item 2.02
Results of Operations and Financial Condition.
On August 14, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the six months ended June 30, 2025, and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated August 14, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1.
Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward-looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics’ future financial performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the Press Release. For further information on other risk factors, please refer to the “Risk Factors” contained in Galectin Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission, and its subsequent filings with the SEC.
The information in this Item 2.02 is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Number
Description
99.1
Press Release dated August 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Galectin Therapeutics Inc.
Date: August 14, 2025
By:
/s/ Jack W. Callicutt
Jack W. Callicutt
Chief Financial Officer
- 3 -
2025 Q1 Q1 2025 Earnings
8-K May 15, 2025
Q1 2025 Earnings
8-KMay 15, 2025
false0001133416The Nasdaq Stock Market00011334162025-05-152025-05-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 15, 2025
GALECTIN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Nevada
001-31791
04-3562325
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240
NORCROSS, GA 30071
(Address of principal executive office) (zip code)
Registrant’s telephone number, including area code: (678) 620-3186
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol
Name of each exchange on which
registered
Common Stock $0.001par value per share
GALT
The Nasdaq Stock Market
SECTION 2 – FINANCIAL INFORMATION
Item 2.02
Results of Operations and Financial Condition.
On May 15, 2025, Galectin Therapeutics Inc. (“Galectin Therapeutics”) issued a press release announcing its results of operations and financial condition as of and for the three months ended March 31, 2025 and provided a business update. Galectin hereby incorporates by reference herein the information set forth in its press release dated May 15, 2025 (the “Press Release”), a copy of which is attached hereto as Exhibit 99.1.
Except for the historical information contained in this report, the statements made by Galectin Therapeutics are forward looking statements that involve risks and uncertainties. All such statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Galectin Therapeutics’ future financial performance could differ significantly from the expectations of management and from results expressed or implied in the Press Release. Forward-looking statements in the Press Release are subject to certain risks and uncertainties described in the Press Release. For further information on other risk factors, please refer to the “Risk Factors” contained in Galectin Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission, and its subsequent filings with the SEC.
The information in this Item 2.02 is being furnished, not filed, pursuant to Item 2.02 of Form 8-K. Accordingly, the information in Item 2.02 of this report, including the Press Release attached hereto as Exhibit 99.1, will not be incorporated by reference into any registration statement filed by Galectin under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference.
SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
99.1
Press Release dated May 15, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Galectin Therapeutics Inc.
Date: May 15, 2025
By:
/s/ Jack W. Callicutt
Jack W. Callicutt
Chief Financial Officer
-3-
Compare GALT vs Leading Stocks
See how GALT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.